10/22/2010

Neoprobe plans to submit to the FDA a biologic-license application for RIGScan, a cancer-targeting drug. The move is among the agency's prerequisites to conduct clinical studies. The company is also looking to file an investigational new-drug application for the agent later.

Full Story:
MedCityNews.com

Related Summaries